Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Trelstar Prior Auth & Coverage | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentViva HealthPolicy IC-0131

    Trelstar (triptorelin pamoate) (Intramuscular) — Prior authorization, dosing, and renewal criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0131 alerts

    Get alerted when Policy IC-0131 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines prior authorization, dosing limits, initial approval, and renewal criteria for Trelstar (triptorelin pamoate IM) across multiple indications (e.g., prostate cancer, CPP, gender dysphoria, breast cancer, fertility preservation, uterine fibroids, head and neck cancer, uterine sarcoma) for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyTrelstar (triptorelin pamoate) (Intramuscular) — Prior authorization, dosing, and renewal criteria
    Policy CodePolicy IC-0131
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with indication-specific documentation; initial approvals generally issued for 12 months (6 months for endometriosis/uterine leiomyomata).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial PA validity (standard)
    6 monthsInitial PA (endometriosis/fibroids)
    6 unitsMax units (prostate)
    <13CPP eligibility age
    J3315HCPCS code

    Coverage and Medical Necessity Criteria

    inv-01: Initial Approval - General

    Covered when ALL of the following are met:

    General criteria: Member is at least 18 years of age (unless otherwise specified)18 years

    Applies unless indication-specific age limits exist (e.g., CPP)

    inv-02: Initial Approval - Prostate Cancer

    Prostate Cancer — Covered when ALL of the following are met:

    Prostate cancer prior therapy requirement: Patient must have a contraindication, intolerance, or failure to Camcevi, Eligard, AND Firmagon prior to consideration of Trelstarprior failure/intolerance/contraindication to three agents

    This is a step requirement before Trelstar

    Policy Summary
    PayerViva Health
    PolicyTrelstar (triptorelin pamoate) (Intramuscular) — Prior authorization, dosing, and renewal criteria
    Policy CodePolicy IC-0131
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with indication-specific documentation; initial approvals generally issued for 12 months (6 months for endometriosis/uterine leiomyomata).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaInitial Therapy Requirements by IndicationRenewal and Continuation TherapyBilling, Codes, and Dosing UnitsQuantity and Unit Billing GuidancePrior Authorization, Documentation, and Denial RisksStep Therapy / Prior TreatmentsAdministration Setting and Billing GuidanceAppendices: Codes and Diagnosis ListsDefinitions and Clinical TermsClinical BackgroundPolicy Revision History

    inv-03: Initial Approval - Central Precocious Puberty

    Central Precocious Puberty (CPP) — Covered when ALL of the following are met:

    CPP criteria: Member is less than 13 years of age AND onset of secondary sexual characteristics earlier than age 8 (females) or 9 (males) associated with pubertal pituitary gonadotropin activation; diagnosis confirmed by pubertal gonadal sex steroid levels and pubertal LH response to native GnRH stimulation; bone age advanced >2 SD beyond chronological age; tumor has been ruled out by appropriate imaging/labs; will not be used in combination with growth hormoneage <13; bone age >2 SD

    Multiple diagnostic tests and tumor exclusion required

    inv-04: Initial Approval - Gender Dysphoria

    Gender Dysphoria — Covered when ALL of the following are met:

    Gender dysphoria criteria: Member has experienced pubertal development to at least Tanner stage 2 (applies only to members <18 years); diagnosis of gender dysphoria confirmed by a qualified mental health professional OR DSM-5-TR criteria; a qualified MHP has confirmed persistent/intense pattern of gender dysphoria, worsening with puberty, addressed coexisting problems, and sufficient capacity to consent; member has been informed of effects/side effects including fertility impact and options for fertility preservation; informed consent obtained (and parental/guardian involvement when adolescent has not reached legal age of consent); for adolescents, pediatric endocrinologist or clinician experienced in pubertal assessment confirms agreement in indication and absence of medical contraindicationsTanner stage >=2 for members <18

    Requires documentation from MHP and, for adolescents, pediatric endocrinologist

    inv-05: Initial Approval - Endometriosis

    Endometriosis — Covered when ALL of the following are met:

    Endometriosis: Member's diagnosis has been confirmed by a workup/evaluation (versus presumptive treatment)diagnostic confirmation

    Documentation of workup required

    inv-06: Initial Approval - Uterine Leiomyomata

    Uterine Leiomyomata (fibroids) — Covered when ALL of the following are met:

    Uterine fibroids: Member's diagnosis has been confirmed by a workup/evaluation (versus presumptive treatment) AND member is receiving iron therapydiagnostic confirmation plus iron therapy

    Initial approval limited to 6 months and renewals not allowed

    inv-07: Initial Approval - Breast Cancer

    Breast Cancer — Covered when ALL of the following are met:

    Breast cancer scenarios: Either: premenopausal woman with hormone receptor–positive disease used in combination with adjuvant endocrine therapy OR used in combination with endocrine therapy for recurrent unresectable or stage IV disease; OR male (sex assigned at birth) used in combination with aromatase inhibitor therapyhormone receptor-positive disease for women; combination therapy for men

    Member must be premenopausal if female

    inv-08: Initial Approval - Fertility Preservation

    Fertility Preservation During Chemotherapy — Covered when ALL of the following are met:

    Fertility preservation: Member is premenopausal AND receiving cytotoxic chemotherapy with potential to cause ovarian damage AND has failed or is not a candidate for other fertility preservation methods (e.g., cryopreservation)premenopausal status; active cytotoxic chemotherapy

    Renewals allowed annually while receiving concomitant chemotherapy

    inv-09: Initial Approval - Head and Neck Cancer

    Head and Neck Cancer — Covered when ALL of the following are met:

    Head and neck cancer: Member has salivary gland tumors AND used in combination with abiraterone and prednisone AND member has androgen-receptor positive recurrent disease with one of: distant metastases; unresectable locoregional recurrence with prior radiation therapy; or unresectable second primary with prior radiation therapyandrogen-receptor positive recurrent disease with specified scenarios

    Combination therapy requirement

    inv-10: Initial Approval - Uterine Sarcoma

    Uterine Neoplasms - Uterine Sarcoma — Covered when ALL of the following are met:

    Uterine sarcoma: Diagnosis of low-grade stage II-IV endometrial stromal sarcoma or adenosarcoma without sarcomatous overgrowth AND ER/PR+ disease AND member is premenopausal and not suitable for surgery AND used for small tumor volume or indolent growth after total hysterectomy AND used in combination with anastrozole, letrozole, or exemestaneER/PR+ and premenopausal status

    Combination endocrine therapy required

    inv-11: Indication-specific medical necessity

    Covered when ALL of the following are met for each indication

    Central Precocious Puberty (CPP): Member is less than 13 years of age AND disease response as indicated by lack of progression or stabilization of secondary sexual characteristics, decrease in height velocity, decrease in BA:CA ratio, and improvement in final height prediction.age <13

    From policy CPP criteria.

    Gender Dysphoria: Member has shown a beneficial response to treatment as evidenced by routine monitoring of clinical pubertal development (if applicable) and applicable laboratory parameters.clinical and lab monitoring

    From policy gender dysphoria coverage statement.

    Fertility Preservation During Chemotherapy: Member is still receiving treatment with cytotoxic chemotherapy.active chemotherapy

    From policy fertility preservation statement.

    Dosing/Administration: Dose and frequency must match one of the listed regimens for the specific indication (see dosing thresholds).per indication dosing regimens

    From Dosage/Administration section.

    Renewal for uterine leiomyomata (fibroids) is explicitly limited: initial authorization is granted per the initial approval criteria, but renewals are not permitted after the initial approval period. When submitting an initial request, include documentation confirming the diagnosis by workup/evaluation and evidence of concurrent iron therapy, as these elements are required for the initial approval and there is no pathway for extension beyond the initial authorization for this indication.

    For central precocious puberty (CPP), the policy requires the member to be younger than 13 years of age. Requests for members who are 13 years or older do not meet the CPP age criterion described in the policy and therefore are not eligible under this CPP-specific coverage pathway.

    Medicare rules may supersede this policy for Part B outpatient drugs. Applicable NCDs, LCDs, LCAs, and other CMS/MAC guidance must be followed when submitting claims or requests for Medicare beneficiaries; these determinations can take precedence. The policy also notes that additional indications may be applied at the discretion of the health plan.

    Renewal may be denied when the member no longer meets indication‑specific renewal criteria or if there is evidence of unacceptable toxicity from the drug. Examples of unacceptable toxicities listed include hypersensitivity reactions, tumor flare, severe QT/QTc prolongation, metabolic syndrome (e.g., hyperglycemia, diabetes, hyperlipidemia), cardiovascular events (e.g., myocardial infarction, stroke), convulsions, and severe cutaneous adverse reactions (including SJS/TEN, DRESS, and AGEP). Confirm ongoing eligibility at each renewal and document absence of these toxicities and continued meeting of the indication-specific criteria.

    Appendix A (NQTL factor table) documents the plan’s assessment of utilization-management factors for triptorelin. It notes that safety/efficacy and potential for misuse/abuse were not prioritized as reasons for prior authorization, while the indication and drug cost were considerations for applying PA. This table does not itself impose non‑medical‑necessity denials but explains the rationale used when designing PA criteria.

    Initial Therapy Requirements by Indication

    inv-44: Initial Therapy Requirements

    Indication-specific initial approval requirements (summarized):

    General initial: Member meets age requirements and indication-specific diagnostic or prior therapy requirements as specified per indicationsee indication-specific nodes

    Refer to each indication for required documentation

    inv-45: Initial therapy dosing

    Initial dosing regimens by indication

    Prostate Cancer dosing: 3.75 mg IM once every 4 weeks OR 11.25 mg IM once every 12 weeks OR 22.5 mg IM once every 24 weeks.select one regimen

    From Dosage/Administration.

    Breast/Head & Neck dosing: 3.75 mg IM every 4 weeks OR 11.25 mg IM once every 12 weeks.select one regimen

    From Dosage/Administration.

    Gender Dysphoria dosing: 3.75 mg IM at weeks 0, 2, 4 and every 4 weeks thereafter OR 11.25 mg IM once every 12 weeks OR 22.5 mg IM once every 24 weeks.select one regimen

    From Dosage/Administration.

    All other indications dosing: 3.75 mg IM every 4 weeks.3.75 mg q4w

    From Dosage/Administration.

    Renewal and Continuation Therapy

    inv-46: Renewal / Continuation Therapy

    Renewal criteria by indication

    Oncology disease response: For prostate cancer, head and neck cancer, breast cancer, and uterine sarcoma: renewal requires disease response as defined by stabilization or decrease in tumor size or spreaddisease stabilization or reduction

    Clinical response documentation required

    CPP response: For CPP: member <13 and demonstration of lack of progression or stabilization of secondary sexual characteristics, decreased height velocity, decreased BA:CA ratio, and improvement in final height predictionclinical and growth parameter improvements

    Objective measures required

    Gender dysphoria response: Member has shown beneficial response evidenced by routine monitoring of pubertal development and applicable labsclinical monitoring showing benefit

    Documentation from treating clinicians required

    Billing, Codes, and Dosing Units

    Dosing/HCPCS unitsHCPCS
    HCPCS unitDescribed as billable units corresponding to mg strengths (e.g., 1 unit = 3.75 mg; 3 units = 11.25 mg; 6 units = 22.5 mg)
    Billing HCPCS CodesHCPCSCovered
    J3315Injection, triptorelin pamoate, 3.75 mg; 1 billable unit = 3.75 mg
    NDCsNDC
    74676-5902-xxTrelstar 3.75 mg single-dose injection kit:74676-5902-xx
    74676-5904-xxTrelstar 11.25 mg single-dose injection kit: 74676-5904-xx
    74676-5906-xxTrelstar 22.5 mg single-dose injection kit: 74676-5906-xx
    Covered Diagnosis Codes (Appendix 1)ICD-10Covered
    C06.9Malignant neoplasm of mouth, unspecified
    C07Malignant neoplasm of parotid gland
    C08.0Malignant neoplasm of submandibular gland
    C08.1Malignant neoplasm of sublingual gland
    C08.9Malignant neoplasm of major salivary gland, unspecified
    C50.011Malignant neoplasm of nipple and areola, right female breast
    C50.012Malignant neoplasm of nipple and areola, left female breast
    C50.021Malignant neoplasm of nipple and areola, unspecified female breast
    C50.022Malignant neoplasm of nipple and areola, unspecified female breast
    C50.029Malignant neoplasm of nipple and areola, unspecified female breast
    1–10 of 69
    1/7
    Covered ICD-10 Diagnosis CodesICD-10Covered
    C50.921Malignant neoplasm of axillary tail of left female breast
    C50.922Malignant neoplasm of axillary tail of left female breast
    C50.929Malignant neoplasm of axillary tail of left female breast
    C50.A0Malignant inflammatory neoplasm of unspecified breast
    C50.A1Malignant inflammatory neoplasm of right breast
    C50.A2Malignant inflammatory neoplasm of left breast
    C54.0Malignant neoplasm of isthmus uteri
    C54.1Malignant neoplasm of endometrium
    C54.2Malignant neoplasm of myometrium
    C54.3Malignant neoplasm of fundus uteri
    1–10 of 164
    1/17
    inv-22: dosing frequency thresholds — Indication-specific thresholds
    Prostate cancerMaximum 6 billable units (22.5 mg) every 168 days
    Gender dysphoria (initiation/maintenance)Loading: 1 billable unit (3.75 mg) at weeks 0, 2, and 4; Maintenance: up to 6 billable units (22.5 mg) every 168 days
    Breast / Head & Neck cancerMaximum 3 billable units (11.25 mg) every 84 days
    All other indications1 billable unit (3.75 mg) every 28 days
    inv-23: Dose intervals — Prostate cancer and other indication-specific interval examples
    Prostate cancer dosing options3.75 mg IM every 4 weeks OR 11.25 mg IM every 12 weeks OR 22.5 mg IM every 24 weeks
    Breast / Head & Neck cancer dosing3.75 mg IM every 4 weeks OR 11.25 mg IM every 12 weeks
    Gender dysphoria dosing (pubertal suppression)3.75 mg IM at weeks 0, 2, 4 then every 4 weeks OR 11.25 mg IM every 12 weeks OR 22.5 mg IM every 24 weeks
    All other indications3.75 mg IM every 4 weeks
    inv-24: F64.9 discontinuation date
    F64.9 statusGender identity disorder, unspecified — Discontinued effective 10/1/26
    ContextListed in Appendix 1 among covered diagnosis codes where F64.9 is explicitly marked as discontinued effective 10/1/26
    inv-25: F64.A effective date
    F64.A statusGender identity disorder, in remission — Effective 10/1/26
    ContextListed in Appendix 1 as the code effective 10/1/26 replacing F64.9 for specified entries

    Quantity and Unit Billing Guidance

    inv-49: Trelstar (triptorelin pamoate) — 6 units (22.5 mg)
    22.5 mg (6 units)Trelstar strength corresponding to 6 billable units (22.5 mg)
    11.25 mg (3 units)Trelstar strength corresponding to 3 billable units (11.25 mg)
    3.75 mg (1 unit)Trelstar single-dose strength corresponding to 1 billable unit (3.75 mg)
    inv-50: Trelstar (triptorelin pamoate) — 1 unit (3.75 mg) at weeks 0,2,4 then up to 6 units (22.5 mg)
    Loading regimen (gender dysphoria)1 unit (3.75 mg) at weeks 0, 2, and 4 followed by maintenance dosing per regimen
    Equivalent strengthsLoading described as 3.75 mg doses; maintenance can use 11.25 mg or 22.5 mg formulations per intervals
    inv-51: Trelstar (triptorelin pamoate) — 3 units (11.25 mg)
    11.25 mg doseRepresents 3 billable units (11.25 mg) used for 84-day dosing intervals for select indications
    Use casesListed for breast cancer and head & neck cancer dosing options
    inv-52: Trelstar (triptorelin pamoate) — 1 unit (3.75 mg)
    3.75 mg single-dose kitRepresents 1 billable unit (3.75 mg) used for q4w dosing or as loading doses
    Billing unit equivalence1 billable unit = 3.75 mg per policy HCPCS unit definition
    inv-53: triptorelin pamoate — Bill per 3.75 mg unit (J3315); select number of units corresponding to chosen strength and dosing interval
    Billing unit definitionJ3315 - Injection, triptorelin pamoate, 3.75 mg; 1 billable unit = 3.75 mg
    Billing instructionSelect and bill the number of J3315 units corresponding to the chosen strength (e.g., 3 units for 11.25 mg, 6 units for 22.5 mg) and dosing interval

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required; validity and renewal intervals

    Prior authorization is required for Trelstar. Initial approvals are generally issued for 12 months (365 days); for endometriosis or uterine leiomyomata the initial approval period is 6 months (180 days). Renewals are available every 12 months (365 days) unless otherwise specified; note that prior authorization for uterine leiomyomata may NOT be renewed and fertility preservation may be renewed annually while the member remains on cytotoxic chemotherapy.

    • Initial PA: 12 months (365 days) standard
    • Initial PA: 6 months (180 days) for endometriosis/uterine leiomyomata
    • Renewals: every 12 months (365 days) unless otherwise specified
    • Uterine leiomyomata: PA may NOT be renewed after initial approval
    • Fertility preservation: renewals allowed annually while receiving cytotoxic chemotherapy
    Prior Authorization

    PA considered for indication and cost reasons

    Prior authorization is applied because authorization depends on the specific clinical indication and the drug cost; these factors are listed as reasons to consider PA in the policy's NQTL assessment.

    • PA considered based on indication
    • PA considered because of drug cost
    Note

    Verify Medicare (Part B) coverage rules and NCD/LCD guidance

    For Medicare Part B members, outpatient drug coverage may be governed by CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and MAC guidance; verify and comply with any applicable NCDs/LCDs/LCAs when submitting requests for Part B beneficiaries.

    • Medicare Part B coverage rules (NCD/LCD/LCA) take precedence where applicable
    • Use the CMS coverage database to identify applicable determinations
    Prior Authorization

    Document prior failure/intolerance to Camcevi, Eligard, and Firmagon for prostate cancer

    For prostate cancer, prior authorization consideration for Trelstar requires documentation that the patient has a contraindication, intolerance, or documented failure to Camcevi, Eligard, AND Firmagon before Trelstar will be considered.

    • Document contraindication, intolerance, or treatment failure to Camcevi, Eligard, and Firmagon
    Step Therapy

    No explicit step therapy sequence provided

    The policy does not specify an explicit step therapy sequence for Trelstar in the provided document portion.

    • No formal step therapy sequence is listed in this policy excerpt
    Note
    Documentation Required

    CPP: required diagnostic confirmation and tumor exclusion

    For central precocious puberty (CPP), documentation must include confirmation by pubertal gonadal sex steroid levels and a pubertal LH response to GnRH stimulation, bone age advanced >2 SD, and appropriate imaging/labs to exclude tumors.

    • Pubertal gonadal sex steroid levels confirming activation
    • Pubertal LH response to native GnRH stimulation
    • Bone age advanced >2 standard deviations
    • Imaging and labs to rule out intracranial or steroid‑secreting tumors (e.g., brain imaging, pelvic/testicular/adrenal ultrasound, hCG levels)
    Documentation Required

    Required clinical documentation showing age and disease response or ongoing treatment

    Clinical documentation submitted for PA or renewal must demonstrate relevant patient age (when applicable), evidence of disease response or ongoing treatment (e.g., CPP: stabilization/lack of progression of secondary sexual characteristics, decreased height velocity and BA:CA ratio, improved final height prediction), and indication‑specific evidence of benefit or continued need.

    • Document member age where relevant (e.g., CPP <13 years)
    • For CPP: show lack of progression/stabilization of secondary sexual characteristics, decreased height velocity, decreased BA:CA ratio, and improved final height prediction
    • For gender dysphoria: routine monitoring showing beneficial pubertal suppression response and applicable lab parameters
    • For fertility preservation: documentation that member remains on cytotoxic chemotherapy
    Billing Rule

    Document and bill with covered ICD‑10 diagnosis codes from Appendix 1

    When submitting claims or PA requests, include an appropriate covered ICD‑10 diagnosis code from Appendix 1 that corresponds to the treated condition (Appendix 1 lists malignant neoplasms, endometriosis, precocious puberty, fertility preservation Z‑codes, and related history codes).

    • Use Appendix 1 ICD‑10 codes relevant to the indication (e.g., C61 for prostate cancer, N80.x for endometriosis, CPP codes listed)
    • Z31.84 for fertility preservation encounters and listed personal history Z85 codes where applicable
    Denial Risk

    Denial risk if unacceptable toxicity is present at renewal

    Renewal may be denied if there is unacceptable toxicity from the drug; listed examples include hypersensitivity reactions, tumor flare, severe QT/QTc prolongation, metabolic syndrome (hyperglycemia/diabetes/hyperlipidemia), cardiovascular events (e.g., myocardial infarction, stroke), convulsions, and severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP).

    • Document absence of unacceptable toxicity at renewal
    • Be aware that listed toxicities are grounds for denial of renewal
    Denial Risk

    Age‑based denial risk for CPP: member must be <13 years

    Requests for CPP for members age 13 years or older do not meet the policy's CPP age criterion and therefore present a denial risk; CPP coverage requires the member to be less than 13 years of age.

    • CPP eligibility: member must be <13 years
    • Requests for CPP in members ≥13 years may be denied
    Denial Risk

    Ensure compliance with applicable Medicare NCDs/LCDs for Part B claims

    For Medicare members, coverage determinations must follow applicable NCDs and LCDs; failure to follow Medicare coverage policies and contractor guidance may result in coverage denial for Part B outpatient drugs.

    • Verify applicable NCDs/LCDs/LCAs and MAC contractor guidance before submitting for Medicare Part B beneficiaries
    • Noncompliance with Medicare coverage determinations may trigger denial

    Step Therapy / Prior Treatments

    Required prior agentsNotes
    Camcevi (relugolix)
    Eligard (leuprolide)
    Firmagon (degarelix)
    Step therapy requirementPolicy note
    No explicit step therapy sequence provided in this document portion
    Prior authorization is considered due to indication and drug cost per the NQTL factor checklist

    Administration Setting and Billing Guidance

    Note

    Administer intramuscularly per dosing schedule; no site‑of‑care restriction specified here

    Administer intramuscularly per the dosing schedule for the selected indication; this portion of the policy does not specify additional site‑of‑care restrictions.

    • Give IM injection at the selected interval (per dosing regimens in Dosage/Administration)
    • No specific office vs. facility site‑of‑care restriction provided in this section
    Billing Rule

    Follow CMS/MAC Part B guidance for hospital outpatient billing

    For Medicare Part B outpatient billing, follow CMS/MAC policies and applicable Part B guidance when the drug is billed to Medicare; verify contractor‑specific requirements for site‑of‑care billing and claims payment.

    • Use CMS Medicare Benefit Policy Manual and MAC guidance for Part B billing
    • Check jurisdiction/MAC contractor guidance listed in Appendix 2 as needed

    Appendices: Codes and Diagnosis Lists

    Covered Diagnosis Codes (Appendix 1) — Appendix mappingICD-10Covered
    See Appendix 1Comprehensive list of covered ICD-10 diagnosis codes for oncology, endometriosis, precocious puberty, fertility preservation, leiomyomata, and related histories as listed in Appendix 1 (see policy Appendix 1 pages).
    Covered ICD-10 Diagnosis Codes — Comprehensive list and selected Z-codesICD-10Covered
    (comprehensive list)Full ICD-10 lists in Appendix 1 covering malignant neoplasms, endometriosis, precocious puberty, leiomyomata, and related codes (see Appendix 1).
    Z31.84Encounter for fertility preservation procedure
    Z85.3Personal history of malignant neoplasm of breast
    Z85.42Personal history of malignant neoplasm of other parts of uterus
    Z85.46Personal history of malignant neoplasm of prostate
    Dosing HCPCS and NDC mappingmixed
    J3315HCPCS J3315 maps to injection, triptorelin pamoate, 3.75 mg (1 billable unit = 3.75 mg); bill units to match 11.25 mg (3 units) and 22.5 mg (6 units) strengths
    74676-5902-xxTrelstar 3.75 mg single-dose injection kit NDC
    74676-5904-xxTrelstar 11.25 mg single-dose injection kit NDC
    74676-5906-xxTrelstar 22.5 mg single-dose injection kit NDC

    Definitions and Clinical Terms

    inv-39: qualified mental health professional — Definition/label for qualified mental health professional
    Minimum qualificationsLicensed by statutory body with at least a master's degree or equivalent in a relevant clinical field from a nationally accredited institution
    Clinical competenciesAble to identify co-existing mental health or psychosocial concerns and distinguish these from gender dysphoria/incongruence/diversity
    Diagnostic competencyCompetent using the latest ICD edition where required for diagnosis and able to assess capacity to consent
    Experience and educationHave experience or qualifications to assess clinical aspects of gender dysphoria and undergo continuing education in related healthcare
    inv-40: DSM-5-TR Gender Dysphoria — DSM-5-TR criteria summary for gender dysphoria in adolescents and adults
    Duration criterionMarked incongruence between experienced/expressed gender and natal gender for at least 6 months
    Manifestations (need ≥2)Examples include incongruence with primary/secondary sex characteristics, strong desire to be rid of or to have characteristics of the other gender, desire to be treated as the other gender, or conviction of having typical feelings/reactions of the other gender
    Associated impactCondition must be associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning
    inv-41: Central Precocious Puberty (CPP) — Onset definitions and policy age specification
    Age of onset definitionOnset of secondary sexual characteristics before age 8 in girls and before age 9 in boys (policy context)
    Policy age limit for coverageMember must be less than 13 years of age to meet CPP criteria for coverage
    Response measures requiredCoverage requires documentation of disease response: lack of progression/stabilization of secondary sexual characteristics, decreased height velocity, decreased BA:CA ratio, and improved final height prediction
    inv-42: Gender dysphoria (pubertal suppression) — Use of GnRH agonists to suppress pubertal progression and coverage tied to documented response
    Therapeutic purposeUse of GnRH agonists to suppress pubertal progression in adolescents with gender dysphoria (pubertal suppression)
    Coverage conditionCoverage tied to documented beneficial response evidenced by routine monitoring of clinical pubertal development and applicable laboratory parameters
    Dosing noteDosing includes loading (3.75 mg at weeks 0, 2, 4) with maintenance options per dosing intervals (q4w, q12w, q24w)
    inv-43: Fertility preservation — Z31.84 encounter for procedures to preserve fertility (listed in Appendix 1)
    Fertility preservation encounter codeZ31.84 — Encounter for fertility preservation procedure (listed in Appendix 1)
    ContextZ31.84 is one of the explicitly listed Z-codes in Appendix 1 relevant to fertility preservation coverage

    Clinical Background

    Triptorelin is a gonadotropin‑releasing hormone (GnRH) agonist indicated across multiple hormone‑responsive conditions. The policy enumerates its use for oncology and benign gynecologic indications as well as pediatric and gender‑related indications, including prostate cancer, central precocious puberty (CPP), gender dysphoria (pubertal suppression), hormone receptor–positive breast cancer in premenopausal women, fertility preservation during cytotoxic chemotherapy, endometriosis, uterine leiomyomata (fibroids), head and neck salivary gland tumors, and certain uterine sarcomas. Coverage requires meeting the indication‑specific diagnostic, prior‑therapy, and monitoring criteria described in the policy.

    Policy Revision History

    2026-07-01policy_reviewLatest

    Policy IC-0131 last reviewed and effective date recorded; renewal and authorization intervals specified (initial PA generally 12 months; endometriosis/uterine leiomyomata initial 6 months; renewals every 12 months unless specified otherwise).

    2026-07-01medicare_guidance_note

    Appendix 2 added/updated clarifying that Medicare Part B coverage (NCDs/LCDs/LCAs) may apply and take precedence and providing CMS coverage search link and jurisdiction listings for contractor MACs.